2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|September 20, 2018
Aptar Pharma Launches Drug Delivery Device at CPhI Worldwide
Author(s)Pharmaceutical Technology Editors
The company will showcase its line of connected devices at and its new PureHale portable drug delivery device designed for upper respiratory care.
Advertisement
On Sept. 12, 2018, Aptar Pharma, a drug delivery systems provider, announced it will be presenting its new PureHale portable drug delivery device, at CPhI Worldwide, which will be held Oct. 9–11, 2018 in Madrid. PureHale is is designed for upper respiratory care.
The company also will be showcasing its new connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes; gamma-sterilized drug delivery components to reduce bioburden; and the company’s Support Services initiative, a portfolio of stage-specific development packages.
In addition to showcasing its product and services, Aptar Pharma executives will be delivering three Pharma Insight Briefings:
- “Debunking the Leachable Myths of Gamma Sterilization: A Migration Study of Steam vs Gamma,” Julie D. Suman, RPh, PhD, president of Next Breath, a division of Aptar Pharma; Tuesday October 9, 11:50 am–12:20 pm. Julie Suman will present a migration study commissioned by Aptar Pharma to assess the impact of both steam sterilization and gamma sterilization on leachable profiles.
“Portable Care for Your Respiratory Tract: Exploring New Technology Platforms,” Guenter Nadler, director Business Development, Aptar Pharma, Tuesday, October 9, 12:30-13:00 pm. Guenter Nadler will discuss new trends in treating upper respiratory tract issues naturally, including new respiratory technology platforms that will meet new market needs.
- “Building a Connected Devices Eco-system for Digital Medicines,” Sai Shankar, director Business Development, Aptar Pharma; Wednesday, October 10, 13:50-14:20 pm.
“Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI and working with our customers to meet their development needs,” said Guillaume Brouet, vice president Analytical, Regulatory and Scientific Affairs at Aptar Pharma, in a
Visit Aptar Pharma at stand 4D10.
Source:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5